Experts are raising alarms over the potential for weight loss injections, such as Ozempic and Wegovy, to cause unexpected weight gain after patients stop treatment. These drugs, known as GLP-1 receptor agonists, have surged in popularity for their ability to suppress appetite and aid rapid weight loss. However, new findings suggest that discontinuing the medication may lead to a rebound effect, where patients regain lost weight—and sometimes even more.
How Do Weight Loss Jabs Work?
These injections mimic a hormone called GLP-1, which regulates blood sugar and slows digestion, helping users feel fuller for longer. Originally developed for type 2 diabetes, they have become a sought-after solution for obesity. Yet, their long-term effects remain under scrutiny.
The Rebound Effect: A Growing Concern
Studies indicate that many patients experience significant weight regain after stopping treatment. Some even surpass their original weight, leading to a cycle of dependency on the medication. Dr. Sarah Jarvis, a GP and medical commentator, warns: "These drugs are not a magic bullet. Without sustained lifestyle changes, the weight will likely return."
NHS Guidelines and Accessibility
While the NHS has approved these drugs for obesity management, strict eligibility criteria apply. Private prescriptions have soared, with clinics offering the jabs for hundreds of pounds per month. Critics argue this creates a two-tier system, where only those who can afford private care benefit.
What’s Next for Weight Loss Treatments?
Researchers are calling for more studies on the long-term impact of GLP-1 drugs. In the meantime, experts emphasise the importance of combining medication with diet and exercise for sustainable results.
